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Michel Labouesse grew up near
Paris. He studied maths and
physics for a degree in
engineering, but subsequently
embraced a career in biology. He
learned genetics during his PhD
with Piotr Slonimski in Gif/Yvette,
where he analysed how the
nuclear genome controls
expression of mitochondrial genes
in yeast. He then went on to learn
developmental biology of the
nematode Caenorhabditis elegans
as a postdoc with Bob Horvitz at
MIT. He is now a group leader at
the Institut de Génétique et
Biologie Moléculaire et Cellulaire
near Strasbourg. His lab focuses
on the analysis of epithelial
morphogenesis in C. elegans.
What turned you on to biology
in the first place? There is a
tradition of science and teaching
in my family, and my parents
were biologists. As a boy, my
imagination was caught by tales
about my great-great-
grandfather, Amiral Ernest
Mouchez (1821–1892), a
geographer and astronomer who
sailed to the southern Indian
Ocean to observe a solar eclipse
by the planet Venus (as a way of
measuring the distance from the
earth to the sun). For me as a
child, science was looking like an
adventure worth all the Jules
Verne novels. As a teenager, I
became attracted to medicine,
but after training in maths and
physics, I eventually elected
genetics because it combined
biology and the logic of maths.
Has any specific paper or
lecture strongly influenced
your research? Certainly! When I
was a graduate student, my
supervisor dragged me to a
seminar by Sydney Brenner, who
described how he and his
colleagues John Sulston and Bob
Horvitz had reconstituted the
complete cell lineage of C.
elegans, still a unique
achievement for any species. As
a former math/physics major, my
general culture in biology was still
thin and I remember the talk as
both a sort of culture shock and
intellectual treat. Though I did not
grasp all the science behind the
talk, I liked the music of it and
quickly decided to do a postdoc
on worms. More recently, a
review in 1994 by Lewis Wolpert
entitled ‘Do we understand
development?’ (Science 266, 571-
572) stimulated me to study
embryonic morphogenesis.
Do you have a ‘favourite’
paper? I very much like the
concision and elegance of the
papers by Michael Brown and
Joe Goldstein on cholesterol
homeostasis. Closer to my own
interests are Jim Priess’s papers
on the early development of C.
elegans embryos — amazing for
their insight and thoroughness.
What is the best advice you’ve
been given? Before I left his lab,
Bob Horvitz gave me the useful
advice that I should get directly
involved in projects that would
form the core of my future lab. I
also received a useful warning
before switching to worms:
everyone strongly advised me
against working on worms, as
there was no tradition of work on
C. elegans in France, and the
country was too small for a new
biological model! It was a good
warning that I should prepare well
if I wanted to succeed with the
model in France.
What has been your biggest
mistake in research? Not to
stay long enough as a postdoc in
the Horvitz lab. Three years is not
enough for a complete training in
a new system. A longer stay
would have spared my lab from
the many small mistakes one
makes when learning a new
approach or implementing a new
strategy for the first time.
Do you have a scientific hero?
Without question it is Sydney
Brenner. His vision of what could
be done with C. elegans, and
courage in taking on such a major
project after being so successful
in solving some of the major
problems in molecular biology,
were breathtaking.
Any views on the ‘electronic
revolution’ in publishing? I
welcome it, with the caveat that
PhD students and colleagues
alike tend to forget the way to the
library... (always a good place to
meet people). As a graduate
student, I learnt a lot while quietly
combing piles of recent Cell
issues for week-end reading; this
useful avenue of communication
is not available if all your reading
is done on-line.
What is your greatest research
ambition? To train students to
be successful, and to contribute
to the culture and economy of the
country that allows me to do my
research.
What do you think are the big
questions to be answered next
in your field? Perhaps because
of my initial training, I am
attracted by issues of physics in
biology. When I look at embryos
and see how cells can change
their shapes, it strikes me that
significant forces must be at work
— not just genes and proteins. A
major challenge is to describe
these forces and to unravel how
the laws of physics influence cell
behavior. Imaging techniques
have advanced considerably in
recent years, and people are now
using single-molecule tracking to
measure nanoforces. It will be a
challenge to adapt such
strategies for embryos, but
bridging genetics and physics in
live animals would be fantastic.
What do you think will be the
likely impact of ‘big’ biology?
As a geneticist, I see it as a novel
strategy for making screens,
made possible by the availability
of complete genome sequences
and advances in computer
science. I welcome it, for it
provides an integrated view of
the cell and brings physiology
back to the limelight. This said,
‘big biology’ is difficult, takes a
lot of resources and is not for the
faint-hearted, not to mention that
such approaches seldom provide
mechanistic explanations of
biological processes. I feel
strongly that it is necessary to
maintain a strong commitment to
the detailed analysis of cellular
processes.
What do you think about the
state of research in France? I
am rather concerned. France has
the financial and human
resources to carry on highly
competitive research, yet it
needs a major overhaul of its
current system. I would like to
convince the Government to
invest much more and for a
longer time in basic science —
applied research won’t be
effective if not supported by
strong academic research. And I
would like to convince many of
my colleagues who are unhappy
with the present situation that we
need changes, to embrace what
is working elsewhere: primarily a
granting agency, local
independence, good contracts
for postdocs. In many ways, the
centralised organisation and
culture of the country is impeding
the development of biology,
which does not naturally operate
on the same (big) scale as
physics. Life science labs have
their own particular needs and
constraints compared to other
branches of science, so
organisational rules devised for
other sciences may hinder
progress and efficiency in biology
if rigidly applied (and vice versa
of course).
....and in Europe? Again, a
granting agency that funds
projects from individual labs is
essential; it does not mean that
the funding of networks should
necessarily be dropped, but that
these should be made much less
artificial. The EMBO has recently
launched a training program to
foster the organisational skills —
grant writing, conflict
management, PhD student
supervision and so forth — of
principal investigators receiving
the ‘young investigator program’
(YIP) award. This is a welcome
initiative, which the EU should
extend.
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Quick guide
Calcineurin
Patrick G. Hogan and Huiming Li
Also known as... Protein
phosphatase 2B (PP2B) and
occasionally Ca2+–calmodulin-
activated protein phosphatase.
Only the Human Genome
Organization nomenclature
committee calls it PP3.
What is it and what does it do?
Calcineurin is a phosphoprotein
serine/threonine phosphatase,
activated physiologically by
Ca2+–calmodulin. In plain
language, calcineurin couples
intracellular Ca2+ to
dephosphorylation of selected
substrates. The biological
consequences are diverse and
depend on the cellular context.
Thus, in mammals, calcineurin
contributes to regulation of
enzymes and ion channels,
chemotaxis and neuronal growth
cone pathfinding, membrane
vesicle trafficking, development of
cardiac valves and osteoclasts,
and genetic programs of
activation in lymphocytes and
differentiation in skeletal muscle.
What does it look like?
Calcineurin is a dimer of an A
catalytic subunit and a B subunit
(Figure 1). Calmodulin becomes
tightly associated with calcineurin
only in the presence of elevated,
but physiological, levels of Ca2+.
In mammals three isoforms of
calcineurin A (Aα, Aβ, Aγ) and two
isoforms of calcineurin B (B1, B2)
are expressed from separate
genes.
Where can it be found?
Calcineurin is present in all
eukaryotes investigated except
higher plants. It is found in all
tissues in mammals, with notably
high levels in brain. Calcineurin
can have a pivotal role in
intracellular signalling even at
relatively low levels, however, as
exemplified in T lymphocytes and
skeletal muscle. In budding yeast,
calcineurin has a role in
coordinating adaptation to
environmental stress both through
the calcineurin–Crz1p
transcriptional pathway and
through post-translational
mechanisms. 
What are its substrates?
Substrates that contribute to
transcriptional signalling, in
particular nuclear factor of
activated T cells (NFAT), have
sometimes overshadowed
calcineurin’s substrates in non-
transcriptional pathways, which
constitute a vast majority of the
identified substrates. Substrate
selection is determined in part by
a docking site in calcineurin that
recognizes the consensus PxIxIT
motif in NFAT and some other
substrates. Since not all
Figure 1. Ribbon diagram
of the calcineurin A (red)–
calcineurin B (green)
dimer from PDB entry
1AUI, with the
autoinhibitory peptide
blocking access to the
bound Fe2+ and Zn2+
(small dark spheres) of
the catalytic site. A region
of calcineurin A whose
structure has not been
determined is indicated
schematically (grey).
Calmodulin (yellow), on
activation by Ca2+, binds
to its target sequence in
calcineurin A and induces
a structural change that
relieves autoinhibition. The structure of the Ca2+–calmodulin–calcineurin A complex
has not been solved, and therefore the structure illustrated is based on the complex
of calmodulin with a cognate peptide. The Ca2+-binding sites of calcineurin B and
calmodulin are shown occupied (large dark spheres). The PxIxIT substrate recognition
site is accessible in resting and activated calcineurin.
